Accendra Health, Inc. · NYSE:ACH
Accendra Health — Q4 2025 Earnings Presentation
7 slides from Accendra Health's earnings presentation, Feb 19, 2026
Slide 1: Fourth Quarter 2025 Continuing Operations Supplemental Slides
Fourth Quarter 2025 Continuing Operations Supplemental Slides February 19, 2026
Slide 2: Forward-Looking Statements and Non-GAAP Disclosure
p. 2 This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This presentation contains certain “forward looking” statements made pursuant to the Safe Har
Slide 3: 2026 Continuing Operations Outlook & Modeling Assumptions
p. 3 2026 Continuing Operations Outlook & Modeling Assumptions Modeling Assumptions(1) Full Year 2026 Outlook Revenue $2.55 - $2.65 billion Adjusted EBITDA (2) $335 - $355 million Interest Expense $115 - $120 million Adjusted Effective Tax Rate 29.0% - 30.0% Diluted Weighted Average Shares Outstandi
Slide 4: Net Revenue Supplemental Information
p. 4 Net Revenue Supplemental Information $2,762 $2,600 2025 Actual Large Commercial Payor Volume Growth Collection Rate Improvement Pricing Growth 2026 Outlook Midpoint Millions $2,000 $2,100 $2,200 $2,300 $2,400 $2,500 $2,600 $2,700 $2,800 $2,900 $3,000
Slide 5: Adjusted EBITDA Supplemental Information
p. 5 $375 $345 Millions $- $50 $100 $150 $200 $250 $300 $350 $400 $450 $500 Adjusted EBITDA Supplemental Information (1) 1. Although the Company does provide guidance for adjusted EBITDA (which is a non-GAAP financial measures), it is not able to forecast the most directly comparable measure calcula
Slide 6: Reconciliation of 2025 Adjusted EBITDA and Free Cash Flow
p. 6 Reconciliation of 2025 Adjusted EBITDA and Free Cash Flow In millions Year Ended December 31, 2025 Loss from continuing operations, net of tax, as reported (GAAP) (103) $ Income tax provision 1 Interest expense, net 107 Acquisition-related charges and intangible amortization 96 Transaction brea
Slide 7: P&HS Sale Proceeds Supplemental Information
p. 7 P&HS Sale Proceeds Supplemental Information (1) Includes customary transaction closing adjustments such as cash, debt like items, and working capital. (2) Represents midpoint of $12 million to $15 million current estimated range. In millions Preliminary purchase price 375 $ Preliminary purchase